Epithelial-to-mesenchymal transition (EMT) is an extreme example of cell plasticity that is important for normal development, injury repair and malignant progression. Widespread epigenetic reprogramming occurs during stem cell differentiation and malignant transformation, but EMT-related epigenetic reprogramming is poorly understood. Here we investigated epigenetic modifications during EMT mediated by transforming growth factor beta. Although DNA methylation was unchanged during EMT, we found a global reduction in the heterochromatin mark H3 Lys9 dimethylation (H3K9Me2), an increase in the euchromatin mark H3 Lys4 trimethylation (H3K4Me3) and an increase in the transcriptional mark H3 Lys36 trimethylation (H3K36Me3). These changes depended largely on lysine-specific demethylase-1 (Lsd1), and loss of Lsd1 function had marked effects on EMT-driven cell migration and chemoresistance. Genome-scale mapping showed that chromatin changes were mainly specific to large organized heterochromatin K9 modifications (LOCKs), which suggests that EMT is characterized by reprogramming of specific chromatin domains across the genome.
EMT is a paradigm of cell plasticity that is characterized by reversible loss of epithelial characteristics coupled with gain of mesenchymal properties 1, 2 . There is evidence that cells undergoing EMT also acquire stem cell traits 3 , and neoplastic epithelial cells undergoing EMT might represent the fraction of cancer 'stem' cells that are thought to be present in many carcinomas 4 .
Epigenetic modifications are potentially reversible alterations in DNA methylation or chromatin that are not associated with changes in DNA sequence. They specify functional outputs from the DNA template and are often heritable through cell division 5, 6 . Genomewide reprogramming of epigenetic modifications occurs during both germ cell development and differentiation of stem cells into somatic cells 7 , and the pathological reprogramming of these modifications contributes to carcinogenesis and other human diseases 5, 8 . Because EMT is characterized by reversible changes in cell type with the acquisition of both stem cell and malignant-type traits, and is important for normal development, injury repair, cancer and other human diseases 9 , we hypothesized that epigenetic changes across the genome might also occur during EMT.
RESULTS

TGF-b-mediated EMT induces changes in chromatin morphology
We induced EMT with transforming growth factor beta (TGF-β), a pleiotropic signaling molecule that is widely used to induce EMT in numerous lineages of cultured epithelial cells 10, 11 . We used AML12 mouse hepatocytes because these cells preferentially undergo EMT when growth-arrested, confluent cultures are treated with TGF-β (refs. [12] [13] [14] [15] . These cells are also not a transformed cell line and should be relatively free of epigenetic changes that might arise secondary to neoplastic transformation 16 .
We confirmed EMT by noting loss of the epithelial adhesion protein E-cadherin and gain of the mesenchymal marker vimentin, two hallmarks of EMT (Supplementary Fig. 1a ). These changes were reversible when we removed TGF-β from the medium and allowed the cells to redifferentiate (Supplementary Fig. 1a ). AML12 cells also showed the EMT-characteristic pattern of reduced cytoplasmic and membranous E-cadherin immunostaining in response to TGF-β ( Supplementary Fig. 1b ). We used immunostaining with Ki67 to confirm that nearly all of the cells were growth arrested and not entering the cell cycle at the beginning of the experiments and during the TGF-β treatments (Supplementary Fig. 1c ), and bromodeoxyuridine (BrDU) to confirm that cell proliferation was minimal during these experiments (Supplementary Fig. 1d ). We also stained the cells with hematoxylin and eosin (H&E), as this is the gold standard by which pathologists visualize changes in cellular morphology 17 (Fig. 1a) . As expected, treatment with TGF-β resulted in reversion from the epithelioid shape of fully differentiated AML12 cells to the classic stellate shape observed during EMT. However, TGF-β also provoked marked changes in nuclear morphology, with nuclear enlargement, oval shape and a transition to 'open' , hypochromatic chromatin with scattered punctate nucleoli ( Fig. 1a) . Transmission electron microscopy of the nuclear ultrastructure showed a smooth, uniform pattern of euchromatin with scattered nucleoli in cells treated with TGF-β, consistent with the H&E stains. Cells treated with TGF-β also showed loss of the electron-dense heterochromatin areas that were observed to invaginate from the nuclear periphery in differentiated cells (Fig. 1b) .
A r t i c l e s These observations are reminiscent of the nuclear features seen in cells reacting to injury in histopathology specimens, and they suggested to us that global epigenetic changes in DNA methylation or chromatin modifications might occur during EMT.
DNA methylation is preserved across the genome during EMT
The changes in chromatin morphology led us to look for genomescale alterations in DNA methylation during EMT. Prolonged culture of proliferative epithelial cells undergoing oncogene-induced, irreversible EMT can eventually result in alterations in DNA methylation at some genes 18 , and transformation-induced changes in DNA methylation might predispose carcinoma cells to undergo EMT 9 . However, there have been no comprehensive investigations into natural changes in DNA methylation during a round of EMT in a non-neoplastic setting, free of transformation-associated epigenetic instability.
We investigated genome-wide DNA methylation during EMT in AML12 cells using comprehensive high-throughput arrays for relative methylation (CHARM) 19, 20 . This approach examines approximately 4.6 million CpG sites in the genome, including almost all CpG islands as well as regions with lower CpG density. These experiments were strongly negative, as pairwise comparisons of different time points after TGF-β stimulation showed no changes in DNA methylation during EMT (for example, Supplementary Fig. 2) . Thus, DNA methylation patterns are faithfully retained during TGF-β treatments and might not strongly contribute to epigenetic plasticity during EMT in this system. These findings could have implications for the preservation of epithelial cell fate during reversible mesenchymal transitions.
Bulk chromatin is globally reprogrammed during EMT
We next investigated whether chromatin modifications changed during EMT. We began by investigating bulk levels of histone H3K9Me2, which seemed an appropriate target as it is found within large, nonrepetitive facultative heterochromatin domains [21] [22] [23] [24] . Western blotting showed that TGF-β induced a reduction in bulk H3K9Me2 that could be reversed by removing TGF-β from the medium ( Fig. 1c,d) .
Immunofluorescence and immunohistochemistry showed that these changes were nuclear ( Supplementary Fig. 3a ), consistent with alterations in chromatin. We used double immunostaining with H3K9Me2 and E-cadherin to confirm that loss of nuclear H3K9Me2 occurred in cells that also lost membranous staining of E-cadherin ( Supplementary Fig. 3b ). Total H3 remained relatively constant throughout TGF-β treatments ( Fig. 1c,d) , and vehicle-treated control cells did not show loss of H3K9Me2 (Supplementary Fig. 4 ). Thus, in contrast to DNA methylation, bulk H3K9Me2 was decreased during EMT mediated by TGF-β.
Outside S-phase, heterochromatin inhibits transcription 25 , and genes in heterochromatin marked by H3K9Me2 are silent 21, 22, 24 . We therefore tested whether chromatin modifications associated with transcription also changed during EMT in parallel with loss of H3K9Me2. Because histone H3K36Me3 in gene bodies is stimulated by active transcription [26] [27] [28] , we measured changes in bulk H3K36Me3 during EMT by western blotting. Bulk H3K36Me3 increased in response to TGF-β ( Fig. 1c,d ) and decreased when we removed TGF-β from the medium, although it had not fallen completely back to baseline by the end of the time course. We also found that H3K36Me3 increased in nuclei during EMT (Supplementary Representative western blots for the indicated histone H3 modifications of bulk histones from AML12 cells treated with TGF-β for the indicated time points. 'TGF-β on' refers to time points during which cells were treated with TGF-β, whereas 'TGF-β off' refers to time points after which TGF-β was removed from the medium, allowing termination of EMT and re-differentiation to hepatocytes (as in Supplementary Fig. 1 ). There was a reversible reduction in H3K9Me2 and increase in H3K4Me3 and H3K36Me3 in response to TGF-β. Total levels of histone H3 remained relatively constant. A r t i c l e s Fig. 5 ). Despite loss of H3K9Me2, there was no increase in H3K9 acetylation ( Supplementary Fig. 6 ), which is sometimes found on demethylated H3 Lys9 residues in euchromatin. This observation could have implications for the re-establishment of H3K9Me2 upon termination of EMT, as H3K9 acetylation inhibits H3K9 methylation. It would therefore be interesting to investigate whether repeated rounds of EMT result in replacement of H3K9Me2 with H3K9 acetylation. We next tested whether bulk histone H3K4Me3 increased during EMT in parallel to H3K36Me3, as H3K4Me3 is typically deposited around transcription start sites to attract protein complexes that remodel chromatin into an open, euchromatic state 27, 28 . We found reversible increases in bulk H3K4Me3 upon TGF-β stimulation ( Fig. 1c,d) , similar to changes seen for H3K36Me3. Vehicle-treated cells did not show similar changes in any of these modifications (Supplementary Fig. 4 ). Collectively, these results indicate that chromatin modifications associated with active transcription and euchromatin increase during EMT in this system, in parallel with loss of heterochromatin.
We also wanted to confirm that reprogramming of bulk chromatin modifications was due to AML12 cells undergoing EMT, rather than to a nonspecific effect of TGF-β. Loss of E-cadherin expression by small inhibitory RNA (siRNA) knockdown can trigger EMT in the absence of exogenous signaling molecules 9, 29, 30 . We therefore tested whether siRNAs against E-cadherin (siEcad) might induce similar changes in bulk chromatin modifications as TGF-β. Incubation of AML12 cultures with siEcad resulted in loss of E-cadherin expression and increases in vimentin, consistent with induction of EMT ( Fig. 1e) . Treatment with siEcad also resulted in a reduction in H3K9Me2 and an increase in H3K4Me3 and H3K36Me3 ( Fig. 1f,g) , similar to the changes seen in EMT mediated by TGF-β. These findings support our conclusion that global reprogramming of chromatin modifications is due to AML12 cells undergoing EMT, rather than being a nonspecific byproduct of TGF-β signaling.
EMT chromatin reprogramming depends on Lsd1
We next sought to identify proteins that might regulate the bulk changes in histone modifications during EMT. Loss of H3K9Me2 in growth-arrested cells suggests this regulation might be due to enzymatic removal rather than to dilution secondary to replication of chromatin. We found that the expression of Lsd1, a dual histone H3 K4 and K9 demethylase 31, 32 , reversibly increased during EMT ( Fig. 2a) . Normally, Lsd1 forms a complex with co-repressors that direct H3K4 demethylation and heterochromatin assembly 31, 33 . Under some circumstances, however, Lsd1 can also form complexes with coactivators that direct H3K9 demethylation and euchromatin assembly 32, 34, 35 . We therefore screened for Lsd1 interactions by largescale immunoprecipitation of endogenous Lsd1 from nuclear extracts of AML12 cells treated with either vehicle or TGF-β, followed by mass spectrometry ( Fig. 2b and Supplementary Table 1 ). Although some known Lsd1-interacting proteins were common to both states (for example, Bhc80, Ctbp and Hmg20), vehicle-treated extracts yielded other proteins including known Lsd1 co-repressors (for example, Rest and CoRest). Extracts that were treated with TGF-β instead yielded a distinct set of proteins, many of which were transcriptional coactivators and have been implicated in the regulation of EMT, chromatin structure and oncogenesis, including several catenins. Thus, treatment Fig. 1 ). Lsd1 expression was increased by TGF-β treatment. (b) Venn diagram summarizing proteins that preferentially immunoprecipitated with Lsd1 from differentiated AML12 cells (vehicle) and those undergoing EMT (TGF-β). Proteins were identified by large-scale immunoprecipitation of endogenous Lsd1 from nuclear extracts followed by mass spectrometry of immunoprecipitates that had been separated on a polyacrylamide gel. 'Both' refers to proteins that immunoprecipitated with Lsd1 under both conditions. We detected several known Lsd1 interactions during both conditions (for example, BHC80, CTBP1 and HMG20A). By contrast, other interactions were specific for vehicle-treated cells, including proteins involved in heterochromatin assembly (for example, CoREST, STAT3 and UBXD2). TGF-β treated cells yielded several proteins that are important for regulation of chromatin, EMT and oncogenesis (for example, several catenins, DEAD box RNA helicases, Rac1 and PARP1). (c) Western blots of the indicated proteins from AML12 cells treated with or without (vehicle-only) TGF-β, and incubated with the siRNAs listed in the panel above the blots. Plus denotes cells that received the indicated treatments, minus denotes cells that did not. siRNAs against Lsd1 but not GFP (control) knocked down Lsd1 expression but did not prevent upstream events that initiate EMT (loss of E-cadherin, gain of vimentin), as shown by western blot. 12 24 36 48 24 48 72   Vehicle  Both  TGF-β   MYST4  STAT3  CoREST  REST  UBXD2  WDR87   TAX1BP1  MED20  SETDB2  MLH1  FANCM   Lsd1  BHC80  CTBP1  CTBP2  Hist. H1   HMG20A  HMG20B  PLOD1  PLOD3  SAP18   DDX5  DDX17  ATP5A  ATP5B  CTNNA  CTNNB  CTNND  CTNNG  TRIM28   ARF4  FUS/TLS  KRAS  Rac1  PABPC1  PKP1  LMNA  PARP1 TGF-β off a b
Ecad We therefore conducted Lsd1 loss-of-function experiments to test whether Lsd1 directed the EMT-associated changes in bulk chromatin modifications. Small interfering RNAs directed against Lsd1 (siLsd1) knocked down protein expression of Lsd1 without interfering with the normal decrease in E-cadherin or the normal increase in vimentin in response to TGF-β ( Fig. 2c) . Although siLsd1 had no effect on the initiation of these upstream aspects of EMT (E-cadherin and vimentin), siLsd1 blocked the TGF-β-mediated loss of H3K9Me2 and partially blocked the TGF-β-mediated increases in bulk H3K36Me3 and H3K4Me3 (Fig. 2d,e ), suggesting that Lsd1 regulates chromatin reprogramming downstream of events (E-cadherin and vimentin) that initate EMT. We also conducted Lsd1 loss-of-function experiments with pargyline, a monoamine oxidase inhibitor that inhibits the ability of Lsd1 to demethylate H3K9Me2 within chromatin 32 , with the caveat that pargyline, like most inhibitors, could have off-target effects that influence EMT independent of Lsd1. Similar to siLsd1, treatment with pargyline did not interfere with the normal loss of E-cadherin or gain of vimentin in response to TGF-β ( Fig. 2f ) and appeared to accelerate these changes. The normal rise in Lsd1 expression was unaffected (Fig. 2f) . Notably, despite enhanced loss of E-cadherin and gain of vimentin, pargyline treatments completely blocked the loss of H3K9Me2 and gain of H3K36Me3 in cells treated with TGF-β ( Fig. 2g,h) , again suggesting that Lsd1 globally reprograms these chromatin modifications downstream of changes in E-cadherin and vimentin. In contrast to siLsd1, treatment with pargyline resulted in further increases in H3K4Me3 in response to TGF-β ( Fig. 2g,h) , possibly due to in vivo inhibition of Lsd1 or other demethylases toward H3K4 (see below). We conclude that the loss of H3K9Me2 and gain of H3K4Me3 and H3K36Me3 during EMT depend in part on Lsd1 and that pargyline abrogates Lsd1-dependent loss of H3K9Me2 and gain of H3K36Me3.
Lsd1 regulates EMT-driven cell motility and chemoresistance
Next, we investigated the functional role of Lsd1-mediated chromatin changes during EMT. We hypothesized that Lsd1-dependent changes in bulk chromatin might regulate phenotypic aspects of EMT downstream of events (such as loss of E-cadherin) that help to initiate EMT in response to TGF-β. We tested this hypothesis with Lsd1 loss-of-function assays as above. A hallmark of EMT is increased cell motility, which confers migratory capabilities. We therefore conducted scratch assays to test whether loss of Lsd1 function affected the migration of AML12 cells treated with TGF-β. Cultures treated with TGF-β showed enhanced migration of individual cells into the scratched area relative to vehicle-treated cells ( Fig. 3a-d) , consistent with increased motility during EMT. Although siLsd1 partially increased migration in vehicle-treated cells, siLsd1 partially inhibited cell migration in cells treated with TGF-β ( Fig. 3a,b) , consistent with the idea that Lsd1 has different functions in differentiated cells than in those undergoing EMT. Pargyline completely inhibited the migration of cells treated with TGF-β, and cells regained their migratory capacity when we removed pargyline from the medium (Fig. 3c,d) . The total abolition of EMTdriven cell migration by pargyline raises the possibility that off-target effects of this inhibitor on other proteins that regulate cell motility might synergize with inhibition of Lsd1 to block cell migration completely during EMT. Thus, loss of Lsd1 function induced by either siRNA knockdown or pargyline treatment interfered with cell migration during EMT, suggesting that Lsd1-mediated changes in chromatin modifications might be important for this phenotype of EMT.
Chemoresistance is another phenotype that is acquired by cells undergoing EMT. We used the topoisomerase inhibitor doxorubicin, A r t i c l e s which causes cytotoxicity by inducing DNA double-strand breaks (DSBs), to investigate chemoresistance. Relative to vehicle-treated controls, AML12 cultures treated with TGF-β showed significant resistance to cell death at high concentrations of doxorubicin (P = 0.037 and 0.030 for 7 µM and 14 µM doxorubicin, respectively, in siRNA experiments; P = 0.042 for 7 µM doxorubicin in pargyline experiments), as measured by calorimetric assays (Fig. 3e,f ). Cultures that were incubated with both TGF-β and siLsd1 did not show significant resistance to cell death (P = 0.142 and 0.232 at 7 µM and 14 µM doxorubicin, respectively), indicating that siLsd1 abolished chemoresistance in cells undergoing TGF-β-mediated EMT (Fig. 3e) . By contrast, treatment with both TGF-β and pargyline caused markedly enhanced chemoresistance, with nearly complete resistance even at concentrations where TGF-β alone had no effect (P = 0.016 and 0.023 at 3.5 µM and 14 µM doxorubicin, respectively; Fig. 3f) . These results suggest that expression of Lsd1 is required to confer EMT chemoresistance whereas Lsd1 demethylase activity may antagonize this phenotype, and highlight how different loss-of-function strategies can sometimes interfere with different aspects of enzyme function, leading to different effects on the same phenotype. We also note that siLsd1 and pargyline treatments resulted in opposite effects on H3K4Me3 during EMT ( Fig. 2d-h) . Deposition of H3K4Me3 at sites of programmed DSBs is required for V(D)J 36, 37 and meiotic recombination 38 , and H3K4Me3 can directly mediate the repair of DSBs in response to exogenous genotoxic agents, independent of its role in transcription 39 . Because siLsd1 reduced EMT-driven H3K4Me3 and chemoresistance, but pargyline further enhanced these two events, we hypothesize that H3K4Me3 might contribute to Lsd1-regulated chemoresistance. We are currently investigating mechanisms whereby Lsd1-dependent chromatin reprogramming, including H3K4Me3, contributes to the repair of DNA damage and chemoresistance during EMT in other studies (see Discussion).
Chromatin reprogramming is targeted to LOCKs
To gain further insight into whether the changes in bulk chromatin were important events during EMT, we wished to identify where in the genome these changes were located. LOCKs are large (100 kb-5 Mb), non-repetitive heterochromatin domains in which H3K9Me2 is enriched, and they overlap with nuclear lamina-associated domains 24, 40 . We examined levels of H3K9Me2 in LOCKs by chromatin immunoprecipitation followed by genomic DNA microarray analysis (ChIP-chip) spanning mouse chromosomes 4-14. Although LOCKs were visible in identical locations in TGF-β-treated and untreated cells, the quantitative levels of H3K9Me2 were reduced across 95.9% (821 of 856) of the LOCKs detected on the arrays in cells treated with TGF-β (Supplementary Data 1 and, for example,  Fig. 4a-c) but not in non-LOCK regions (P = 0; Supplementary  Fig. 7) . These results were verified by replicate ChIP-chip and replicate ChIP-qPCR analyses (Supplementary Fig. 8 ; http://userwww.service. emory.edu/~hwu30/EMT/). In the replicate, 781 of 903 LOCKs (84%) showed H3K9Me2 reduction (P = 0, permutation testing), and the reduction pattern was highly concordant between replicates (P < 10 -12 ). These findings are reminiscent of the quantitative abatement of LOCKs seen in cultured embryonic stem cells and cancer cells 24 .
We next mapped the locations of H3K36Me3 by ChIP-chip. As expected 27, 28 , we detected peaks of H3K36Me3 over gene-coding regions, many of which were identical in differentiated AML12 cells and those treated with TGF-β. When we searched for regions where the level of H3K36Me3 was altered during EMT, we found many regions harboring genes across the genome that showed elevated H3K36Me3 in cells treated with TGF-β (1,736 total regions harboring 1,701 known genes; Supplementary Data 1 and, for example,  Fig. 4a-c) . Most of these genes were located in gene-rich regions between LOCKs, rather than within LOCKs themselves (1,231 of 1,701; 72.3%). Gene ontology analysis 41 of genes with elevated H3K36Me3 during EMT revealed that these genes encoded proteins with EMT-related functions, including cytoskeletal remodeling, cell migration, cell adhesion, Ras signaling and various enzymatic activities (Supplementary Table 2) . These findings are consistent with inhibition of cell migration by siLsd1 and pargyline, which block the accumulation of bulk H3K36Me3 during EMT.
We next mapped H3K4Me3 enrichment by ChIP-chip. As expected 28 , most enrichments manifested as sharp peaks of H3K4Me3 directly over transcription start sites. Most of these were identical in differentiated and TGF-β treated cells and could not account for the increase in H3K4Me3 during EMT. When we searched for the regions that were responsible for increased bulk H3K4Me3 during EMT, we identified 219 large (100 kb-1.4 Mb, mean 260 kb), discrete regions of the genome that contained broad enrichments (rather than sharp peaks) of newly acquired H3K4Me3. Most (86.8%) of these new domains were distributed over a subset of 190 LOCKs (P = 0, Supplementary Table 3 , Supplementary Data 1 and, for example, Fig. 4a-c) , comprising 21.1% of all LOCKs detected on our arrays (P = 0; Supplementary Table 3 ). Although LOCKs on average are AT rich and gene poor, the K4Me3 LOCKs were GC rich and gene rich (Fig. 4d,e) . One-third of K4Me3 LOCKs were flanked by regions with newly acquired H3K36Me3 at their boundaries (P = 0; Fig. 4a-c  and Supplementary Table 3) , and most K4Me3 LOCKs (76%) were flanked by regions with either pre-existing or newly acquired H3K36Me3 (P = 0; Supplementary Table 3 ). Gene ontology analysis of genes in K4Me3 LOCKs revealed sets of genes that were distinct from those enriched with H3K36Me3, including those involved in glycoprotein activities, ion balance, plasma membrane signaling, extracellular functions and development ( Supplementary Table 4 ). Replicate ChIP-qPCR analysis over a region from chromosome 4 supported the ChIP-chip findings for H3K36Me3 and H3K4Me3 at this locus (Supplementary Fig. 9 ).
Although many genes at LOCK boundaries were enriched with H3K36Me3 during EMT, most known genes in K4Me3 LOCKs did not acquire this modification (18 of 262, 6.9%), suggesting that genes at the boundaries but not within the K4Me3 LOCKs themselves are transcriptionally active during EMT. Consistent with this, there was elevated mRNA expression of genes at K4Me3 LOCK boundaries but not those within the LOCKs during EMT, and absolute mRNA levels of genes in K4Me3 LOCKs were very low relative to those for other genes (Fig. 4a-c) . Further studies are needed to determine whether K4Me3 LOCKs 'poise' chromatin for transcriptional activation as has been proposed for bivalent domains that contain both H3K4Me3 and H3K27Me3 (ref. 42) or whether they serve other functions during EMT, such as triggering the release of LOCK subsets from the nuclear lamina or participating in a surveillance DNA damage response (DDR), as proposed for large-scale changes in chromatin structure 43 .
Lsd1 is enriched in a K4Me3 LOCK during EMT
We next selected a K4Me3 LOCK to map chromatin-bound Lsd1 in differentiated AML12 cells and in those undergoing TGF-β-mediated EMT. We investigated the region shown in Figure 4c , as we found it interesting that the Lsd1 gene was present at one of the LOCK boundaries. We therefore performed ChIP for Lsd1 with 31 PCR primers spaced across this 500-kb locus. In differentiated cells, peaks of Lsd1 were present over the 5′ regions of the genes at the LOCK boundaries (Lsd1 and Epha8). These findings are similar to those of other studies A r t i c l e s in lower eukaryotes that have reported peaks of Lsd1 enrichment at euchromatin-heterochromatin boundaries, where it functions to maintain boundaries between large domains of heterochromatin and euchromatin 44 . Unexpectedly, Lsd1 became enriched across the entire K4Me3 LOCK in chromatin isolated from cells treated with TGF-β, and there were new Lsd1 peaks within the gene bodies of Lsd1 and Epha8 (Fig. 4f) . The appearance of Lsd1 across an entire LOCK depleted of H3K9Me2, in conjunction with blockade of H3K9Me2 demethylation by siLsd1 and pargyline, suggests that Lsd1 may acquire the ability to demethylate H3K9Me2 substrates during EMT.
In contrast to the loss of Lsd1 in this K4Me3 LOCK induced by siLsd1 (Fig. 4g) , pargyline did not affect Lsd1 enrichment across this LOCK during EMT (Fig. 4h) . This is not unexpected because pargyline inhibits the demethylase activity but not the protein expression of Lsd1. As the spectrum of proteins that interacted with Lsd1 shifted toward transcriptional coactivators during EMT (Fig. 2b) , including several catenins which can recruit H3K4Me3 methyltransferase activity to chromatin 45 , the increase in EMT-driven H3K4Me3 during pargyline treatments (Fig. 2g,h) is probably due to recruitment of such proteins by Lsd1 during EMT, coupled with inhibition of H3K4 demethylase activity by pargyline. Determination of the precise mechanisms by which Lsd1 mediates epigenetic reprogramming of LOCKs and other regions of the genome during EMT will require extensive investigations into the roles of the various Lsd1 protein interactions identified in Figure 2b , including genome-wide mapping of Lsd1 and the partners with which it interacts during EMT. (Fig. 4i) . This reprogramming might be crucial for proper execution of EMT functions, as inhibition of bulk chromatin changes by Lsd1 loss-of-function had marked effects on cell migration and chemoresistance. Finally, it is likely that many other chromatin modifications not examined here are also reprogrammed during EMT. The repression of epithelium-specific genes during EMT may be mediated by H3K27Me3 through a Snai1-dependent process, and forced overexpression of Snai1 can also recruit Lsd1 to epithelial genes to assist in repression 46 , which suggests that Lsd1 might have dual roles in repressing and activating areas of the genome that are important for EMT. In this regard, the balance of Lsd1-interacting factors identified in Figure 2b might have a key role in directing Lsd1 toward activation or repression. It has been proposed that cells undergoing EMT acquire stem cell traits 3, 4 . Our findings of quantitative abatement of LOCKs and elevated levels of H3K36Me3 across the genome during EMT supports this notion at the level of chromatin, as previous studies have shown similar results for cultured ESCs 24, 47 . By contrast, other studies have reported that the reverse process, mesenchymal-to-epithelial transition (MET), is required to produce induced pluripotent stem cells (iPSCs) from fibroblasts 48, 49 . These findings raise the possibility that the reverse chromatin changes described here might occur during the generation of iPSCs. Alternatively, the process described here could be a general mechanism for increasing epigenetic plasticity and reprogramming, regardless of cell fate directionality.
EMT is also characterized by the acquisition of malignant-type traits. Reduction of LOCKs is seen in various malignant human cancer cell lines 24 , similar to our EMT results. The enrichment of H3K36Me3 at numerous genes involved in cell motility is also common to both EMT and malignancy. Indeed, Lsd1 loss-of-function experiments interfered with both H3K36Me3 and cell migration during EMT.
We also consider that a shift in balance from heterochromatic (H3K9Me2) to euchromatic (H3K4Me3) and transcription-coupled (H3K36Me3) modifications might increase susceptibility to DNAdamaging agents during stress, injury or malignancy. Other cells with euchromatic genomes seem to activate a surveillance DDR to cope with this threat 43 , although this could generate chromosomal rearrangements at sites of hyperactive transcription 50, 51 . Thus, if a surveillance DDR was activated concomitant with elevated transcription across the genome during EMT, this might confer robust repair of DNA damage at the expense of generating mutations.
This possibility would be compatible with a surveillance role for H3K4Me3 in repair of DSBs during EMT, consistent with the effects of siLsd1 and pargyline on H3K4Me3 and chemoresistance. Our ChIP-chip results revealed that K4Me3 LOCKs were specifically situated in large gene-rich and CG-rich regions of the genome flanked by genes with high levels of transcription, which are prone to acquire DSBs in response to genotoxic agents such as doxorubicin [50] [51] [52] . Indeed, components of the DDR (such as γH2AX) must spread several hundred kilobases from a DSB to facilitate repair, and heterochromatin inhibits this process 43 . We therefore hypothesize that one function of K4Me3 LOCKs might be to provide a euchromatic scaffold in gene-rich regions of the genome that allows efficient spreading of the DDR through large heterochromatin domains in response to DSBs that might occur during EMT, thereby conferring robust repair of DSBs and enhanced chemoresistance.
Like stem cell differentiation 7, 27 , germ cell development 53 and malignant transformation 5, 8 , epigenetic reprogramming during EMT is mediated by widespread changes in chromatin modifications. Unlike reprogramming in these other cell types, DNA methylation patterns are faithfully preserved during EMT. Further studies in other cell systems are needed to determine whether our findings are a general property of EMT and whether similar epigenetic reprogramming occurs in other physiological contexts. 
METHODS
Methods
